Abstract:1297 Objectives The standard uptake value (SUV) of 18F-FDG PET/CT is important in the diagnosis and treatment response evaluation of lung cancer. The aim of the present study is to investigate the clinical value of SUV of 99mTc-3PRGD2 SPECT/CT in lung cancer diagnosis. Methods Twenty-four patients with pathologically approved lung cancer (21 non-small cell lung cancer and 3 small cell lung cancer),4 patients with benign diseases (3 pulmonary consolidation and 1 adenoma), and 6 healthy volunteers were enrolled in the study. All subjects were injected with 629.0-921.3 MBq of 99mTc-3PRGD2 (mean ± SD, 759.3 ± 80.1 MBq), and a SPECT/CT (Discovery NM/CT 670, GE Healthcare) was performed 30 minutes later. The images were analyzed using Q.Metrix (GE Healthcare) after OSEM reconstruction with resolution recovery technology, scatter correction and Xray CT based attenuation correction. The mean SUV (SUVmean) and the maximum SUV (SUVmax) of the superior, middle, and inferior mediastinum and the right lower lobe of the liver in healthy volunteers, as well as the corresponding values of the primary lesions in the patients, were measured with a 3 cm-diameter volume of interest (VOI). The longest diameters of the primary lesions in CT images of the patients were measured as well. Results The median age of the lung cancer patients, benign disease patients and healthy volunteers was 60.5 (43-76) years old, 62.0 (52-76) years old and 56.0 (44-64) respectively. Fourteen of the 24 lung cancer patients (58.3%), 2 of the 4 benign disease patients (50%) and 3 of the 6 healthy volunteers (50%) were male. The mean value of the SUVmean and the SUVmax of the superior, middle, and inferior mediastinum were 0.64 ± 0.27 g/ml and 1.06 ± 0.41 g/ml. The SUVmean and the SUVmax of the right lower lobe of the liver in healthy volunteers were 1.85 ± 0.72 g/ml and 2.35 ± 0.92 g/ml. The longest diameter of the primary lesion in CT images in the 24 lung cancer patients was 3.68 ± 2.02 cm; the corresponding SUVmean and SUVmax values were 1.67 ± 1.04 g/ml and 3.68 ± 2.12 g/ml. In the 4 benign lesions, the longest diameter in CT images was 2.60 ± 0.45 cm, and the SUVmean and SUVmax were 0.64 ± 0.27 g/ml and 0.96 ± 0.36 g/ml, respectively. The diagnostic sensitivity, specificity and accuracy of SUVmean and SUVmax of 99mTc-3PRGD2 in lung carcinoma verses the mean + 2SD of mediastinum were 0.67, 1.00, 0.71 and 0.67, 1.00, 0.71, respectively. Conclusions (1) The mean + 2SD of the SUV mean and SUVmax of mediastinum seems a valid threshold for 99mTc-3PRGD2 SPECT/CT in lung carcinoma diagnosis; (2) SUV of 99mTc-3PRGD2 SPECT/CT, as an indicator of lung cancer, is in good compliance and accordance with pathological diagnosis. The SUV of 99mTc-3PRGD2 SPECT/CT is a promising tool in the diagnosis and differential diagnosis of lung cancer. RESEARCH SUPPORT: This work was financially supported, in part, by the National Natural Science Foundation of China (NSFC) projects (Grant No.81071188, 81571713 and 81171369) and Beijing Municipal Science & Technology Commission (Grant No.Z151100003915133)

Clinical Value of 99Mtc-Deoxy-glucose Derivative SPECT/CT in Tumors

[Value of 18F-FDG Metabolic Imaging in Diagnosis and Treatment of Head and Neck Tumors and Its Mechanism Study].

Clinical Significance of FDG Single-Photon Emission Computed Tomography: Computed Tomography in the Diagnosis of Head and Neck Cancers and Study of Its Mechanism.

Clinical value of ~(18)F-FDG PET/CT in diagnosis of malignant tumors

Evaluation of 99Mtc-Cn5dg As a Broad-Spectrum SPECT Probe for Tumor Imaging

18F-FDG PET/CT in the application of intracranial tumors

[The Clinical Application of 18F-Fluorodeoxyglucose Coincidence Imaging in Lymphoma].

Clinical value of 99 Tc m -octreotide SPECT/CT in diagnostics of lung cancer

Clinical Evaluation of (18)F-FDG-SPECT/CT Imaging in Diagnosis and Staging of Patients with Suspected Lung Cancer

Novel 99Mtc-Labeled Glucose Derivative for Single Photon Emission Computed Tomography: A Promising Tumor Imaging Agent

Synthesis and biological evaluation of a &lt;sup&gt;99m&lt;/sup&gt;Tc-labeled glucose derivative for tumor imaging

Value of Dual-Phase ~(18)F-FDG PET in Diagnosis of Tumor

Diagnosis Ability of Dual-Phase F-18-fluoro-2-deoxy-D-glucose SPECT/PET for Distinguishing the Benign and Malignant Lesions

Comparison of 18F-FDG Coincidence SPECT Imaging and Computed Tomography in the Initial Staging and Therapeutic Evaluation of Lymphomas

Evaluation of Standard Uptake Value of 99Mtc-3Prgd2 Spect/Ct in Lung Cancer Diagnosis

Clinical Value of PET/CT Imaging with 18F-FDG in the Breast Disease of Malignant and Benign Lesion

Clinical value of 18F-FDG PET/CT in combination with mammography and ultrasound in diagnosis of breast cancer

The Differential Diagnostic Value of 99Tcm-Mibi SPECT/CT Fusion Imaging for Lung Lesions

Integrin Receptor Imaging 99Mtc-3Prgd2 SPECT/CT in Diagnosis and Lymph Node Staging of Non-Small Cell Lung Cancer

Application of 11C-Choline and 18F-FDG PET/CT in Diagnosing Brain Glioma

The Preparation and Execution of Exploratory Human Studies on Novel 99Mtc-Labeled Glucosamine Derivatives Containing Different Phenyl Isonitriles As Promising Tumor Imaging Agents.